Share this story:

Canadian Children's Hospital to Receive Ventripoint VMS+ 3.0 For Clinical Assessment of Pediatric Cardiac Patients





Toronto, Ontario - TheNewswire - July 15, 2019 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company") (TSXV:VPT) (OTCQB:VPTDF) is pleased to announce that a leading Canadian Children's Hospital will be the first pediatric hospital to receive the VMS+ 3.0 complete heart analysis system for the clinical assessment of pediatric cardiac patients.

"The VMS+ 3.0 heart analysis system is especially useful in children with heart problems, which often involve the right side of the heart." commented Desmond Hirson, Ventripoint President. "It is wonderful to have the new system being applied to children so shortly after being licensed by Health Canada for clinical use."

The VMS+ 3.0 system is a cost-effective diagnostic tool for measuring whole heart function in pediatric and adult patients utilizing standard 2D ultrasound to obtain volumetric measurements and ejection fractions for all 4 chambers of the heart. The new compact and portable system can be set up within minutes providing a streamlined approach within the clinical echo environment where patient case load is continually increasing. It is also the only approved way to generate substantially equivalent results to the gold standard MRI.

The VMS+ 3.0 system is now commercially available in Canada and Europe. The system is for investigational use in the United States and pending pre-market 510K clearance by the FDA.

About Ventripoint Diagnostics Ltd.

Ventripoint's technology is a leading Artificial Intelligence (AI) approach known as Knowledge-Based Reconstruction (KBR), used to create applications to monitor heart disease, a leading cause of death worldwide. The VMS+ is the first cost-effective and accurate AI tool for measuring whole heart function using conventional ultrasound. The Company has developed a suite of applications for all major heart diseases and is actively commercializing the approach to improve cardiac care.

For further information please contact:

Dr. George Adams, CEO, Telephone: (519) 803-6937

Email: gadams@ventripoint.com

Forward Looking Statements:

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Corporation. Although the Corporation believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Corporation can give no assurance that they will prove to be correct. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Other factors, which could materially affect such forward-looking information are described in the risk factors in the Corporation's most recent annual management's discussion and analysis that is available on the Corporation's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Corporation undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release